Evaxion receives positive feedback on patent application for ai-based novel cancer vaccine target identification method

Copenhagen, denmark, june 26, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.
EVAX Ratings Summary
EVAX Quant Ranking